Jump to main content
Jump to site search

Issue 9, 2017
Previous Article Next Article

Microengineered biomimetic ocular models for ophthalmological drug development

Author affiliations

Abstract

Current ophthalmological drug discovery and testing methods have limitations and concerns regarding reliability, ethicality, and applicability. These drawbacks can be mitigated by developing biomimetic eye models through mathematical and experimental methods which are often referred to as “eye-on-a-chip” or “eye chip”. These eye chip technologies emulate ocular physiology, anatomy, and microenvironmental conditions. Such models enable understanding of the fundamental biology, pharmacology, and toxicology mechanisms by investigating the pharmacokinetics and pharmacodynamics of various candidate drugs under ocular anatomical and physiological conditions without animal models. This review provides a comprehensive overview of the latest advances in theoretical and in vitro experimental models of the anterior segment of the eye and its microenvironment, including eye motions and tear film dynamics. The current state of ocular modeling and simulation from predictive models to experimental models is discussed in detail with their advantages and limitations. The potential for future eye chip models to expedite new ophthalmic drug discoveries is also discussed.

Graphical abstract: Microengineered biomimetic ocular models for ophthalmological drug development

Back to tab navigation

Publication details

The article was received on 03 Feb 2017, accepted on 01 Apr 2017 and first published on 03 Apr 2017


Article type: Critical Review
DOI: 10.1039/C7LC00112F
Citation: Lab Chip, 2017,17, 1539-1551
  •   Request permissions

    Microengineered biomimetic ocular models for ophthalmological drug development

    Z. Estlack, D. Bennet, T. Reid and J. Kim, Lab Chip, 2017, 17, 1539
    DOI: 10.1039/C7LC00112F

Search articles by author

Spotlight

Advertisements